NewsRoom Articles - Page 109 of 115

WednesdayDec 06, 2017 12:03 pm

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Providing Clinical Proof of Cannabis Efficiency

Veritas Pharma is unlocking the science underlying medical cannabis Clinically profiling select cannabis strains - pharmacologically identifying strains for specific disease conditions Entering human clinical studies with valuable IP’s in place There is growing support for medicinal cannabis. Repeated peer-reviewed studies have demonstrated positive patient responses in a variety of maladies. However, to date, the response has been largely anecdotal, and, unlike rigorous pharmacology, the precise mechanisms and chemical profiles of cannabinoids remain unknown. Through exacting scientific protocols, Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is about to radically change the understanding and applications of this millennia-old medicine.…

MondayDec 04, 2017 9:21 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Wins in Vegas!

Major interest generated in Lexaria’s technology at MJBizCon Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand…

WednesdayNov 29, 2017 9:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Offers a Sweet Escape for Cannabis Users without Smoking or Sweeteners

Proprietary lipophilic enhancement technology boosts bioavailability of orally ingested cannabinoids and masks unpleasant taste Only company in the world to obtain a patent for improved oral or ingestible delivery of all cannabinoids, including both non-psychoactive and psychoactive Company generates revenue from out-licensing its technology The cannabis market is exploding globally as well as domestically, and Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has pioneered an enabling technology that enhances the body’s absorption of cannabinoids—an advancement from which many cannabis-related companies can profit. Lexaria’s proprietary lipophilic enhancement technology has demonstrated the ability to boost the bioavailability of all orally ingested cannabinoids.…

TuesdayNov 21, 2017 10:15 am

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is “One to Watch”

Management, R&D team boasts decades of industry leadership Pipeline includes therapies targeting chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder Unique result-driven strategy strongly positions Veritas in the medical marijuana industry Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas’ R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma’s goal is to perform clinical…

MondayNov 13, 2017 3:34 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Driving Cannabis Costs Down While Meeting Patient Needs

Strong cash position of over $40 million to fund aggressive expansion timeline One of first companies to obtain cannabis production license from Health Canada Infrastructure in place to take advantage of projected $9 billion Canadian cannabis market Sees ample opportunities in Western Europe with first marketing push in Germany Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), a manufacturer and distributor of medical cannabis in Canada, is creating a consistent, organically grown, pesticide-free standardized product that is keeping costs down and investors excited. Abcann’s approach to growing cannabis centers on replicating the natural environment of any geographical location for a product…

WednesdayNov 08, 2017 2:41 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Boosts Revenue by Out-Licensing Patented Technology to Third-Party Partners

High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018 LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing its patented global technology related to ingestion of edible cannabinoids at a rate of 5-10% of gross sales to its third-party partners. LXRP has also expanded its process of improved and faster inhalation by the body of fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) in pain…

TuesdayNov 07, 2017 11:05 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Supplements Popular Beverage with Legal CBD

Unique patented drug delivery platform Active in world’s largest beverage market Technology that compliments rather than competes with CBD companies An old and popular beverage is being supplemented in a healthy, flavorful way now that Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is on the scene. Having increased its ownership stake in PoViva Tea, LLC from 51% to 100%, the innovative drug delivery biotech plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. After water, tea is the most widely consumed beverage in the world and is an ideal adjuvant…

WednesdayOct 25, 2017 2:54 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Seeks to Become A ‘Global Presence’

Sees opportunities for legalized marijuana marketing in Canada, Germany, all of Western Europe and South America Armed with $43 million in working capital, it sees advantages for itself in product and financing It has a proprietary process in its indoor growing environment to control temperature, humidity and water to produce standardized, pesticide-free cannabis ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://cnw.fm/SvJr1). The company sells in…

MondayOct 23, 2017 3:41 pm

Liberty Leaf Holdings Ltd. (OTCQB: LIBFF) (CSE: LIB) (FSE: HN3P) Subsidiary Plans to Boost Storage Capacity

In new business plan sent to Health Canada, subsidiary North Road Ventures proposes doubling its cannabis product lines, adding oil products (CBD) and boosting by five-fold its storage capacity Statista report projects Canadian marijuana market will reach C$2.8 billion by 2020 Company sees cannabis oil products accounting for 50% or more of projected sales Liberty Leaf Holdings Ltd.’s (OTCQB: LIBFF) (CSE: LIB) (FSE: HN3P) wholly own subsidiary, North Road Ventures, has abridged its application to Health Canada, detailing its plans to double its cannabis product lines, adding cannabis oil products (CBD), and boost by five-fold its vault storage capacity to…

FridayOct 20, 2017 9:19 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) to Hold Web-Meeting on November 1

Web-meeting scheduled for November 1, 2017, at 4:15 p.m. ET 19 patents filed encompassing 44 countries Patents cover broad range of lipophilic bio-actives including cannabinoids, vitamins and other pharma Patented lipophilic delivery system proven to improve bio-absorption The medical effectiveness of cannabinoids is no longer in question, and the cannabinoid market proliferates ever faster as more people realize the therapeutic benefits. However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is subsequently excreted by the body, causing onset times and efficacy to vary wildly. With 19 patent applications filed internationally covering 44 countries,…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977